Menu Search
Equities

Omnicell Inc

OMCL:NSQ

Omnicell Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)44.87
  • Today's Change0.76 / 1.72%
  • Shares traded391.03k
  • 1 Year change+33.46%
  • Beta0.7760
Data delayed at least 15 minutes, as of Nov 22 2024 19:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Omnicell Inc's revenues fell -11.48% from 1.30bn to 1.15bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 5.65m to a loss of 20.37m.
Gross margin41.44%
Net profit margin-1.66%
Operating margin-3.33%
Return on assets-0.78%
Return on equity-1.46%
Return on investment-1.11%
More ▼

Cash flow in USDView more

In 2023, Omnicell Inc increased its cash reserves by 41.99%, or 148.14m. The company earned 181.09m from its operations for a Cash Flow Margin of 15.79%. In addition the company generated 23.42m cash from financing while 55.02m was spent on investing.
Cash flow per share1.45
Price/Cash flow per share30.57
Book value per share26.59
Tangible book value per share5.20
More ▼

Balance sheet in USDView more

Omnicell Inc has a Debt to Total Capital ratio of 31.72%, a lower figure than the previous year's 47.91%.
Current ratio1.05
Quick ratio0.9529
Total debt/total equity0.4645
Total debt/total capital0.3172
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -466.11%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		49.28
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.